Now showing items 1-8 of 8

    • Molina Berríos, Alfredo Enrique; Campos Estrada, Carolina; Lapier, Michel; Duaso, Juan; Kemmerling Weis, Ulrike; Galanti Garrone, Norbel; Leiva, Mario; Ferreira, Jorge; López Muñoz, Rodrigo; Maya Arango, Juan (Elsevier, 2013)
      Objectives: To evaluate the effect of benznidazole on endothelial activation in a murine model of Chagas disease. Methods: A low (30 mg/kg/day) and a high (100 mg/kg/day) dose of benznidazole were administered to mice ...
    • López Muñoz, Rodrigo; Molina Berríos, Alfredo Enrique; Campos Estrada, Carolina; Abarca-Sanhueza, Patricio; Urrutia-Llancaqueo, Luis; Peña-Espinoza, Miguel; Maya Arango, Juan (Frontiers Media S.A., 2018)
      © 2018 López-Muñoz, Molina-Berríos, Campos-Estrada, Abarca-Sanhueza, Urrutia-Llancaqueo, Peña-Espinoza and Maya. Pathogenic trypanosomatids (Trypanosoma cruzi, Trypanosoma brucei, and Leishmania spp.) are protozoan parasites ...
    • Seguel, Verónica; Castro, Lorena; Reigada, Chantal; Cortés, Leonel; Díaz, María V.; Miranda, Mariana R.; Pereira, Claudio A.; Lapier, Michel; Campos Estrada, Carolina; Morello Casté, Antonio; Kemmerling Weis, Ulrike; Maya, Juan D.; Lopez Muñoz, Rodrigo (Elsevier, 2016)
      Benznidazole is the first-line drug used in treating Chagas disease, which is caused by the parasite Trypanosoma cruzi (T. cruzi). However, benznidazole has limited efficacy and several adverse reactions. Pentamidine is ...
    • Díaz, María V.; Miranda, Mariana R.; Campos Estrada, Carolina; Reigada, Chantal; Maya Arango, Juan; Pereira, Claudio A.; López Muñoz, Rodrigo (Elsevier, 2014)
      Pentamidine is an antiprotozoal and fungicide drug used in the treatment of leishmaniasis and African trypanosomiasis. Despite its extensive use as antiparasitic drug, little evidence exists about the effect of pentamidine ...
    • Molina Berríos, Alfredo Enrique; Campos Estrada, Carolina; Lapier, Michel; Duaso, Juan; Kemmerling Weis, Ulrike; Galanti Garrone, Norbel; Ferreira, Jorge; Morello Casté, Antonio; López Muñoz, Rodrigo; Maya Arango, Juan (Springer, 2013)
      Chronic Chagas’ disease affects 10–30 % of patients infected with Trypanosoma cruzi, and it mainly manifests as cardiomyopathy. Important pathophysiological mechanisms involved in the cardiac lesions include activation of ...
    • Molina Berríos, Alfredo Enrique; Campos Estrada, Carolina; Henríquez, Natalia; Faúndez, Mario; Torres, Gloria; Castillo, Christian; Escanilla, Sebastián; Kemmerling Weis, Ulrike; Morello Casté, Antonio; López Muñoz, Rodrigo; Maya Arango, Juan (PLoS, 2013)
      Chagas’ disease, produced by Trypanosoma cruzi, affects more than 8 million people, producing approximately 10,000 deaths each year in Latin America. Migration of people from endemic regions to developed countries has ...
    • Molina Berríos, Alfredo Enrique; Campos Estrada, Carolina; Henriquez, Natalia; Faúndez, Mario; Torres, Gloria; Castillo, Christian; Escanilla, Sebastián; Kemmerling Weis, Ulrike; Morello Casté, Antonio; López Muñoz, Rodrigo; Maya Arango, Juan (Public Library of Science, 2013)
      Chagas' disease, produced by Trypanosoma cruzi, affects more than 8 million people, producing approximately 10,000 deaths each year in Latin America. Migration of people from endemic regions to developed countries has ...
    • Campos Estrada, Carolina; Liempi, Ana; González Herrera, Fabiola; Lapier, Michel; Kemmerling Weis, Ulrike; Pesce Reyes, Bárbara; Ferreira, Jorge; López Muñoz, Rodrigo; Maya Arango, Juan (Public Library of Science, 2015)
      © 2015 Campos-Estrada et al.Trypanosoma cruzi is the causal agent of Chagas Disease that is endemic in Latin American, afflicting more than ten million people approximately. This disease has two phases, acute and chronic. ...